CN101389351B - 人抗il-23抗体、组合物、方法和用途 - Google Patents
人抗il-23抗体、组合物、方法和用途 Download PDFInfo
- Publication number
- CN101389351B CN101389351B CN2006800535467A CN200680053546A CN101389351B CN 101389351 B CN101389351 B CN 101389351B CN 2006800535467 A CN2006800535467 A CN 2006800535467A CN 200680053546 A CN200680053546 A CN 200680053546A CN 101389351 B CN101389351 B CN 101389351B
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- sequence
- variable region
- people
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Description
符号 | 说明 |
- | 无抑制 |
-/+ | 微弱抑制 |
+/- | 弱,不完全抑制 |
+ | 抑制 |
* | 不结合没有His标记的连接的rhIL-23(来自R&D Systems) |
** | 比CNTO IL-12更好地抑制R&D IL-12 |
*** | 在高浓度导致细胞死亡 |
N/d | 未进行 |
克隆# | VL | L-CDR1 (SEQ ID No:) | L-CDR2 (SEQ ID NO:) | L-CDR3 (SEQ ID No:) | 注释 |
4083 | κ3 | RASQSVLGNYLA(46) | GASSRAT(52) | HQYGSISTT(58) | 主要命中 |
5267 | QQYSHLLIT(59) | 亲和力成熟 | |||
5268 | QQYSHISLT(60) | 亲和力成熟 | |||
5269 | QQFAHILLT(61) | 亲和力成熟 | |||
4190 | K3 | RASQ SVS SNYLA(47) | YASRRAT(53) | QQTSNTPFT(62) | 主要命中 |
4190EV | QQTSNTPFT | 加上E1&V86取代 | |||
5029 | QQFITYLPT(63) | 亲和力成熟 | |||
5030 | QQDALSPFT(64) | 亲和力成熟 | |||
5031 | QQDRGTPFT(65) | 亲和力成熟 | |||
5032 | QQSLNIPFT(66) | 亲和力成熟 | |||
5057 | QQDTSSPFT(67) | 亲和力成熟 | |||
4190x | QQb1b2b3b4b5b6FT##(68) | 预测的 | |||
4205 | λ1 | SGSSSNIGSYYVN(48) | GNTHRPS(54) | QTYASLGPGEV(69) | 主要命中 |
4217 | κ1 | RASQSIFYNLA(49) | GASNRAT(55) | QQYSSEPVT(70) | 主要命中 |
4649 | λ1 | TGSSSNIGSGYDVH(50) | GNSKRPS(56) | SSWT--PSSVV(71) | 主要命中 |
5058 | SSWTDTPNMIV(72) | 亲和力成熟 | |||
5059 | ASWTDGLSLVV(73) | 亲和力成熟 | |||
5059QS | ASWTDGL SLVV | 加上Q1,S2取代 | |||
4649x | a1SWTDa2a3a4a5a6V++(74) | 预测的 | |||
4658 | λ2 | TGTS SDVGGYNSVS(51) | SVSSRPS(57) | SSYDTNKPLVV(75) | 主要命中 |
5060 | GSYDVYGRFYV(76) | 亲和力成熟 | |||
5061 | SSYYFYLQRIV(77) | 亲和力成熟 | |||
5062 | QTYYFSYSGPV(78) | 亲和力成熟 | |||
5063 | GSWDPIFSYEV(79) | 亲和力成熟 |
Claims (37)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75488905P | 2005-12-29 | 2005-12-29 | |
US60/754,889 | 2005-12-29 | ||
PCT/US2006/062674 WO2007076524A2 (en) | 2005-12-29 | 2006-12-28 | Human anti-il-23 antibodies, compositions, methods and uses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210297501.1A Division CN102887954B (zh) | 2005-12-29 | 2006-12-28 | 人抗il-23抗体、组合物、方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101389351A CN101389351A (zh) | 2009-03-18 |
CN101389351B true CN101389351B (zh) | 2012-10-10 |
Family
ID=38218878
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800535467A Active CN101389351B (zh) | 2005-12-29 | 2006-12-28 | 人抗il-23抗体、组合物、方法和用途 |
CN201210297501.1A Active CN102887954B (zh) | 2005-12-29 | 2006-12-28 | 人抗il-23抗体、组合物、方法和用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210297501.1A Active CN102887954B (zh) | 2005-12-29 | 2006-12-28 | 人抗il-23抗体、组合物、方法和用途 |
Country Status (37)
Country | Link |
---|---|
US (9) | US7935344B2 (zh) |
EP (4) | EP3219328B1 (zh) |
JP (1) | JP5193881B2 (zh) |
KR (1) | KR101210395B1 (zh) |
CN (2) | CN101389351B (zh) |
AU (1) | AU2006330411B2 (zh) |
BR (1) | BRPI0620946B8 (zh) |
CA (1) | CA2635692C (zh) |
CR (1) | CR10181A (zh) |
CY (4) | CY1115935T1 (zh) |
DK (3) | DK2548577T3 (zh) |
EA (2) | EA035459B1 (zh) |
EC (1) | ECSP088591A (zh) |
ES (3) | ES2807928T3 (zh) |
GT (1) | GT200800132A (zh) |
HK (1) | HK1124548A1 (zh) |
HN (1) | HN2008000988A (zh) |
HR (3) | HRP20140982T1 (zh) |
HU (3) | HUE034269T2 (zh) |
IL (5) | IL192458A (zh) |
LT (3) | LT3219328T (zh) |
LU (1) | LUC00071I2 (zh) |
MX (2) | MX2008008621A (zh) |
MY (2) | MY162559A (zh) |
NI (1) | NI200800193A (zh) |
NL (1) | NL300935I2 (zh) |
NO (4) | NO343345B1 (zh) |
NZ (1) | NZ569546A (zh) |
PL (3) | PL1971366T3 (zh) |
PT (3) | PT2548577T (zh) |
RS (3) | RS60616B1 (zh) |
SG (1) | SG10201505755YA (zh) |
SI (3) | SI2548577T1 (zh) |
SV (1) | SV2008002972A (zh) |
UA (1) | UA101301C2 (zh) |
WO (1) | WO2007076524A2 (zh) |
ZA (1) | ZA200806556B (zh) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
JP2009501006A (ja) | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | 抗il−23抗体、組成物、方法および用途 |
PL1937721T3 (pl) * | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
EP1931710B1 (en) | 2005-08-31 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
AU2006284841B2 (en) | 2005-09-01 | 2012-11-08 | Merck Sharp & Dohme Corp. | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
CA2678749C (en) | 2007-02-23 | 2018-03-13 | Schering Corporation | Engineered anti-il-23p19 antibodies |
US20100111966A1 (en) | 2007-02-23 | 2010-05-06 | Schering Corporation | Engineered anti-il-23p19 antibodies |
CA2679400A1 (en) | 2007-02-28 | 2008-09-04 | Schering Corporation | Combination therapy for treatment of immune disorders |
WO2009042162A2 (en) | 2007-09-25 | 2009-04-02 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
EP2650311A3 (en) * | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
KR102469853B1 (ko) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
CA2734919C (en) * | 2008-08-27 | 2016-08-16 | Schering Corporation | Lyophilized formulations of engineered anti-il-23p19 antibodies |
WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US20110020392A1 (en) * | 2008-10-14 | 2011-01-27 | Salubrious Pharmaceutical, Llc | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
CN102257131A (zh) | 2008-12-19 | 2011-11-23 | 先灵公司 | 用于哺乳动物细胞培养的给料添加剂及使用方法 |
WO2011017294A1 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
KR101836217B1 (ko) * | 2009-10-30 | 2018-03-08 | 얀센 바이오테크 인코포레이티드 | Il-17a 길항제 |
GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
ES2776980T3 (es) | 2009-12-23 | 2020-08-03 | Merck Sharp & Dohme | Línea celular 3M |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
BR112013009083B1 (pt) | 2010-10-13 | 2021-08-10 | Janssen Biotech, Inc. | Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada |
EA030436B1 (ru) | 2010-11-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | АНТИТЕЛА К IL-23p19 ИЛИ ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ, ИХ ПРИМЕНЕНИЕ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭТИ АНТИТЕЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ВЫДЕЛЕННЫЕ ПОЛИНУКЛЕОТИДЫ, ЭКСПРЕССИОННЫЕ ВЕКТОРЫ И КЛЕТКИ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
EP2866833B1 (en) | 2012-06-27 | 2019-05-15 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
US9657111B2 (en) | 2012-11-29 | 2017-05-23 | Bayer Healthcare Llc | Humanized monoclonal antibodies against activated protein C and uses thereof |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
US9113892B2 (en) | 2013-01-08 | 2015-08-25 | Covidien Lp | Surgical clip applier |
TWI636063B (zh) * | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合il-23之抗體 |
EA201591579A1 (ru) | 2013-03-15 | 2016-01-29 | Амген Инк. | Способы лечения болезни крона при помощи анти-il-23 антитела |
EP3689369A1 (en) | 2013-03-15 | 2020-08-05 | Amgen, Inc | Methods for treating psoriasis using an anti-il-23 antibody |
EP3415534A1 (en) | 2013-05-10 | 2018-12-19 | Numab Therapeutics AG | Bispecific constructs and their use in the treatment of various diseases |
US9801900B2 (en) | 2013-11-22 | 2017-10-31 | Mary Kay Inc. | Compositions for sensitive skin |
WO2015114426A2 (en) * | 2014-01-30 | 2015-08-06 | Massimo Zanotti | A method for monitoring the respect of well-being of live poultry intended for slaughter |
US20150224078A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers |
SI3104853T1 (sl) | 2014-02-10 | 2020-03-31 | Respivant Sciences Gmbh | Zdravljenje s stabilizatorji mastocitov za sistemske motnje |
EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
AR101753A1 (es) | 2014-09-03 | 2017-01-11 | Boehringer Ingelheim Int | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
RU2746356C2 (ru) | 2014-12-19 | 2021-04-12 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
PE20221834A1 (es) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina |
EA201791734A1 (ru) | 2015-02-04 | 2018-01-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения воспалительных заболеваний |
KR20170110129A (ko) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
AU2016247921A1 (en) | 2015-04-14 | 2017-08-31 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
MX2018003376A (es) | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
CA3007098A1 (en) | 2015-12-22 | 2017-06-29 | Amgen Inc | Ccl20 as a predictor of clinical response to il23-antagonists |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
EP3443005A1 (en) | 2016-04-15 | 2019-02-20 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
MX2019003703A (es) * | 2016-09-30 | 2020-08-13 | Janssen Biotech Inc | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. |
EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
WO2018071504A2 (en) | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
AU2017362222A1 (en) | 2016-11-16 | 2019-05-30 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-IL-23 specific antibody |
US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3459968A1 (en) * | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
JP2021515770A (ja) * | 2018-03-05 | 2021-06-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗il−23特異的抗体を用いたクローン病の治療方法 |
TWI744617B (zh) | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
US20190345245A1 (en) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
AU2019300491A1 (en) | 2018-07-13 | 2021-03-04 | Astrazeneca Collaboration Ventures, Llc | Treating ulcerative colitis with brazikumab |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
WO2020104943A2 (en) | 2018-11-20 | 2020-05-28 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il-23 specific antibody |
KR20210096559A (ko) * | 2018-11-27 | 2021-08-05 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항IL-23p19 항체 및 이의 용도 |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
JP2022525145A (ja) | 2019-03-14 | 2022-05-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体組成物を生成するための製造方法 |
JP2022534020A (ja) * | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク,インコーポレーテツド | Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
CN110564694B (zh) * | 2019-09-23 | 2021-07-13 | 华东师范大学 | 分泌il-23抗体的靶向前列腺癌的car-t细胞药物 |
EP4077378A1 (en) | 2019-12-20 | 2022-10-26 | NovaRock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
KR20230006551A (ko) * | 2020-05-05 | 2023-01-10 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 크론병을 치료하는 방법 |
CN111718414B (zh) * | 2020-06-12 | 2021-03-02 | 江苏荃信生物医药有限公司 | 抗人白介素23单克隆抗体及其应用 |
TW202224702A (zh) | 2020-09-10 | 2022-07-01 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
IL305802A (en) | 2021-03-12 | 2023-11-01 | Janssen Biotech Inc | A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody |
EP4305062A1 (en) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
CA3219846A1 (en) | 2021-05-28 | 2022-12-01 | Venkatesh Krishnan | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
AU2022306973A1 (en) | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
CN115785267B (zh) * | 2021-09-10 | 2023-12-15 | 三优生物医药(上海)有限公司 | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 |
WO2023051798A1 (zh) * | 2021-09-30 | 2023-04-06 | 江苏恒瑞医药股份有限公司 | 抗il23抗体融合蛋白及用途 |
WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
US20230212280A1 (en) * | 2021-12-17 | 2023-07-06 | Janssen Biotech, Inc. | IL-23 Specific Antibodies for the Treatment of Systemic Sclerosis |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108425A1 (en) * | 2004-05-10 | 2005-11-17 | Cytos Biotechnology Ag | Il-23 p19 antigen array and uses thereof |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
EP0229046B1 (fr) | 1985-03-30 | 1994-05-04 | BALLIVET, Marc | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
CH671155A5 (zh) | 1986-08-18 | 1989-08-15 | Clinical Technologies Ass | |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
JP2647427B2 (ja) | 1987-04-24 | 1997-08-27 | 帝人株式会社 | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
EP0486526B2 (en) | 1989-08-07 | 2001-03-07 | Peptech Limited | Tumour necrosis factor binding ligands |
ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
JP3112463B2 (ja) * | 1990-03-27 | 2000-11-27 | 雪印乳業株式会社 | モノクローナル抗体の作製方法 |
TW212184B (zh) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DE69128362T2 (de) | 1990-06-01 | 1998-05-20 | Chiron Corp | Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
WO1992014843A1 (en) | 1991-02-21 | 1992-09-03 | Gilead Sciences, Inc. | Aptamer specific for biomolecules and method of making |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ATE359842T1 (de) | 1991-07-02 | 2007-05-15 | Nektar Therapeutics | Abgabevorrichtung für nebelförmige medikamente |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
AU5322494A (en) | 1992-10-02 | 1994-04-26 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
EP0665759B1 (en) | 1992-10-19 | 1998-12-23 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
EP0680451B1 (en) | 1993-01-19 | 1998-11-04 | Glaxo Group Limited | Aerosol dispenser and method of manufacture |
WO1994018317A1 (en) | 1993-02-12 | 1994-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
AU692239B2 (en) | 1994-03-07 | 1998-06-04 | Medarex, Inc. | Bispecific molecules having clinical utilities |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
CZ212598A3 (cs) | 1996-01-03 | 1998-11-11 | Glaxo Group Limited | Inhalační zařízení |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
JP2001517692A (ja) | 1997-09-29 | 2001-10-09 | インヘール セラピューティック システムズ, インコーポレイテッド | ネブライザにおける使用のための安定化調製物 |
WO1999040195A1 (en) | 1998-02-06 | 1999-08-12 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
DE69942607D1 (de) | 1998-04-14 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000009552A1 (en) | 1998-08-14 | 2000-02-24 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
AU3873200A (en) | 1999-03-11 | 2000-09-28 | Schering Corporation | Mammalian cytokines; related reagents and methods |
US6800460B1 (en) | 1999-03-11 | 2004-10-05 | Schering Corporation | Mammalian cytokine complexes |
JP2002543840A (ja) | 1999-05-19 | 2002-12-24 | インサイト・ゲノミックス・インコーポレイテッド | 細胞外シグナル伝達分子 |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
MXPA02002684A (es) | 1999-09-09 | 2002-07-30 | Schering Corp | Citocinas de mamifero; reactivos y metodos relacionados. |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
US20020042096A1 (en) * | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
ATE396264T1 (de) | 2000-05-10 | 2008-06-15 | Schering Corp | Zytokinrezeptoruntereinheit-proteine aus säugetieren, damit zusammenhängende reagenzien und methoden |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
ITPD20010108A1 (it) | 2001-05-08 | 2002-11-08 | Fidia Advanced Biopolymers Srl | Biomateriali polimerici elettricamente conduttori, loro processo di preparazione ed impiego nel settore biomedico sanitario. |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CN1711282B (zh) | 2002-10-30 | 2010-05-26 | 健泰科生物技术公司 | Il-17产生的抑制 |
AU2003298816C1 (en) | 2002-12-02 | 2010-12-16 | Amgen Fremont, Inc. | Antibodies directed to Tumor Necrosis Factor and uses thereof |
AU2003303384A1 (en) | 2002-12-23 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
ZA200506159B (en) * | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
AU2004219625B9 (en) * | 2003-03-10 | 2010-12-23 | Merck Sharp & Dohme Corp. | Uses of IL-23 agonists and antagonists; related reagents |
US20040185506A1 (en) * | 2003-03-21 | 2004-09-23 | Heavner George A. | Epitope mapping using nuclear magnetic resonance |
JP2007515939A (ja) * | 2003-05-09 | 2007-06-21 | セントカー・インコーポレーテツド | IL−23p40特異的免疫グロブリン由来タンパク質、組成物、方法および用途 |
US20050033029A1 (en) | 2003-06-30 | 2005-02-10 | Jin Lu | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
ES2541436T3 (es) * | 2004-02-06 | 2015-07-20 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
ATE533502T1 (de) | 2004-02-17 | 2011-12-15 | Schering Corp | Verfahren zur modulation der il-23-aktivität; relevante reagenzien |
US7501247B2 (en) | 2004-05-03 | 2009-03-10 | Schering Corporation | Method of treating skin inflammation |
AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
US20060194981A1 (en) * | 2005-02-26 | 2006-08-31 | Jass Paul A | Process for preparation of probucol derivatives |
JP2009501006A (ja) | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | 抗il−23抗体、組成物、方法および用途 |
PL1937721T3 (pl) | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
EP1931710B1 (en) | 2005-08-31 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9353645B1 (en) | 2015-02-16 | 2016-05-31 | Borgwarner Inc. | Vane ring thermal strain relief cuts |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2006
- 2006-12-28 HU HUE12174197A patent/HUE034269T2/en unknown
- 2006-12-28 RS RS20200911A patent/RS60616B1/sr unknown
- 2006-12-28 EP EP17156111.1A patent/EP3219328B1/en active Active
- 2006-12-28 CN CN2006800535467A patent/CN101389351B/zh active Active
- 2006-12-28 SG SG10201505755YA patent/SG10201505755YA/en unknown
- 2006-12-28 EP EP20180279.0A patent/EP3760230A1/en active Pending
- 2006-12-28 RS RS20140565A patent/RS53685B1/en unknown
- 2006-12-28 DK DK12174197.9T patent/DK2548577T3/en active
- 2006-12-28 SI SI200632156A patent/SI2548577T1/sl unknown
- 2006-12-28 LT LTEP17156111.1T patent/LT3219328T/lt unknown
- 2006-12-28 SI SI200632385T patent/SI3219328T1/sl unknown
- 2006-12-28 PL PL06846836T patent/PL1971366T3/pl unknown
- 2006-12-28 AU AU2006330411A patent/AU2006330411B2/en active Active
- 2006-12-28 WO PCT/US2006/062674 patent/WO2007076524A2/en active Application Filing
- 2006-12-28 HU HUE17156111A patent/HUE049832T2/hu unknown
- 2006-12-28 ES ES17156111T patent/ES2807928T3/es active Active
- 2006-12-28 EA EA201301072A patent/EA035459B1/ru unknown
- 2006-12-28 PL PL12174197T patent/PL2548577T3/pl unknown
- 2006-12-28 PT PT121741979T patent/PT2548577T/pt unknown
- 2006-12-28 UA UAA200809846A patent/UA101301C2/ru unknown
- 2006-12-28 LT LTEP12174197.9T patent/LT2548577T/lt unknown
- 2006-12-28 DK DK17156111.1T patent/DK3219328T3/da active
- 2006-12-28 KR KR1020087018522A patent/KR101210395B1/ko active IP Right Grant
- 2006-12-28 PL PL17156111T patent/PL3219328T3/pl unknown
- 2006-12-28 MY MYPI2011001645A patent/MY162559A/en unknown
- 2006-12-28 CN CN201210297501.1A patent/CN102887954B/zh active Active
- 2006-12-28 JP JP2008548853A patent/JP5193881B2/ja active Active
- 2006-12-28 DK DK06846836.2T patent/DK1971366T3/da active
- 2006-12-28 RS RS20170468A patent/RS55963B1/sr unknown
- 2006-12-28 EA EA200870129A patent/EA019476B9/ru active Protection Beyond IP Right Term
- 2006-12-28 EP EP06846836.2A patent/EP1971366B1/en active Active
- 2006-12-28 NZ NZ569546A patent/NZ569546A/en unknown
- 2006-12-28 PT PT171561111T patent/PT3219328T/pt unknown
- 2006-12-28 ES ES12174197.9T patent/ES2622602T3/es active Active
- 2006-12-28 BR BRPI0620946A patent/BRPI0620946B8/pt active IP Right Grant
- 2006-12-28 MX MX2008008621A patent/MX2008008621A/es active IP Right Grant
- 2006-12-28 SI SI200631828T patent/SI1971366T1/sl unknown
- 2006-12-28 EP EP12174197.9A patent/EP2548577B1/en active Active
- 2006-12-28 MY MYPI20082401A patent/MY163032A/en unknown
- 2006-12-28 CA CA2635692A patent/CA2635692C/en active Active
- 2006-12-28 PT PT68468362T patent/PT1971366E/pt unknown
- 2006-12-28 ES ES06846836.2T patent/ES2517420T3/es active Active
- 2006-12-28 US US11/617,503 patent/US7935344B2/en active Active
-
2008
- 2008-06-26 IL IL192458A patent/IL192458A/en active IP Right Grant
- 2008-06-27 HN HN2008000988A patent/HN2008000988A/es unknown
- 2008-06-27 NI NI200800193A patent/NI200800193A/es unknown
- 2008-06-27 SV SV2008002972A patent/SV2008002972A/es unknown
- 2008-06-30 EC EC2008008591A patent/ECSP088591A/es unknown
- 2008-06-30 MX MX2012006997A patent/MX342595B/es unknown
- 2008-07-01 GT GT200800132A patent/GT200800132A/es unknown
- 2008-07-23 NO NO20083266A patent/NO343345B1/no active Protection Beyond IP Right Term
- 2008-07-28 ZA ZA200806556A patent/ZA200806556B/xx unknown
- 2008-07-29 CR CR10181A patent/CR10181A/es not_active Application Discontinuation
-
2009
- 2009-03-18 HK HK09102604.5A patent/HK1124548A1/zh unknown
-
2010
- 2010-08-12 US US12/855,354 patent/US7993645B2/en active Active
-
2011
- 2011-04-04 US US13/079,457 patent/US8106177B2/en active Active
- 2011-06-30 US US13/173,090 patent/US8221760B2/en active Active
-
2012
- 2012-05-20 IL IL219890A patent/IL219890A/en active IP Right Grant
- 2012-06-15 US US13/524,122 patent/US9353181B2/en active Active
-
2014
- 2014-10-14 HR HRP20140982TT patent/HRP20140982T1/hr unknown
- 2014-10-29 CY CY20141100889T patent/CY1115935T1/el unknown
- 2014-12-24 IL IL236427A patent/IL236427A/en active IP Right Grant
-
2016
- 2016-04-29 US US15/142,765 patent/US9783607B2/en active Active
- 2016-11-13 IL IL248917A patent/IL248917A0/en unknown
-
2017
- 2017-05-04 HR HRP20170675TT patent/HRP20170675T1/hr unknown
- 2017-05-04 CY CY20171100485T patent/CY1118880T1/el unknown
- 2017-09-01 US US15/694,107 patent/US10030070B2/en active Active
-
2018
- 2018-04-16 IL IL258718A patent/IL258718A/en unknown
- 2018-04-25 LU LU00071C patent/LUC00071I2/fr unknown
- 2018-04-26 NL NL300935C patent/NL300935I2/nl unknown
- 2018-05-02 HU HUS1800021C patent/HUS1800021I1/hu unknown
- 2018-05-07 CY CY2018013C patent/CY2018013I2/el unknown
- 2018-05-08 LT LTPA2018010C patent/LTC1971366I2/lt unknown
- 2018-06-20 US US16/013,141 patent/US10954297B2/en active Active
-
2019
- 2019-01-04 NO NO20190011A patent/NO344118B1/no unknown
- 2019-07-10 NO NO2019029C patent/NO2019029I1/no unknown
- 2019-08-16 NO NO20190992A patent/NO20190992A1/no unknown
-
2020
- 2020-08-03 HR HRP20201215TT patent/HRP20201215T1/hr unknown
- 2020-08-31 CY CY20201100813T patent/CY1123400T1/el unknown
-
2021
- 2021-02-22 US US17/181,778 patent/US20210188966A1/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108425A1 (en) * | 2004-05-10 | 2005-11-17 | Cytos Biotechnology Ag | Il-23 p19 antigen array and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101389351B (zh) | 人抗il-23抗体、组合物、方法和用途 | |
CN101252951B (zh) | 抗il-23抗体、组合物、方法和用途 | |
CN101415819B (zh) | 抗il-6抗体、组合物、方法及应用 | |
AU2021200025A1 (en) | Human anti-IL-23 antibodies, compositions, methods and uses | |
BRPI0612728A2 (pt) | anticorpos de anti-il-23p19, composições, métodos e usos | |
AU2012238198A1 (en) | Human anti-IL-23 antibodies, compositions, methods and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CENTOCOR INC. Free format text: FORMER OWNER: CENTOCOR INC Effective date: 20121106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: CENTOCOR ORTHO BIOTECHNOLOGY INC. Free format text: FORMER NAME: CENTOCOR INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: American Pennsylvania Patentee after: JANSSEN BIOTECH, Inc. Address before: American Pennsylvania Patentee before: Centocor Ortho Biotech Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121106 Address after: American Pennsylvania Patentee after: CENTOCOR ORTHO BIOTECH Inc. Address before: American Pennsylvania Patentee before: CENTOCOR, Inc. |